Search

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

The European Hematology Association (EHA) Announces a New Era of Partnership with Interplan as its New Core PCO

The European Hematology Association (EHA) is delighted to announce to the conference and meeting community the outcome of its Core PCO Invitation To Tender (ITT).

Read more

‘i4MDS’ consortium wins prestigious EHA Innovation Grant

In a significant development, the International Integrative Innovative Immunology for Myelodysplastic Neoplasms consortium—known as the ‘i4MDS’— has received an esteemed EHA Innovation Grant.

Read more

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Read more

Turning thoughts into reality

Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)

I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.

Read more

EHA and Polish Society’s third tutorial together focused on myeloid and lymphoid leukemias

Seventy-five participants from Europe and the Middle East learned about the advances in biology, genetic characteristics, diagnostic approaches and therapy of leukemias during the EHA-PTHiT Hematology Tutorial on Myeloid and Lymphoid Leukemias in Warsaw, Poland.

Read more